ISS-N1 Makes the First FDA-approved Drug for Spinal Muscular Atrophy

Overview

Journal Transl Neurosci

Specialty Neurology

Date 2017 Apr 13

PMID 28400976

Citations 88

Authors

Eric W Ottesen

Affiliations

Soon will be listed here.

Abstract

Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and infants. SMA is caused by deletions or mutations of () gene. , a nearly identical copy of , cannot compensate for the loss of due to predominant skipping of exon 7. While various regulatory elements that modulate exon 7 splicing have been proposed, intronic splicing silencer N1 (ISS-N1) has emerged as the most promising target thus far for antisense oligonucleotide-mediated splicing correction in SMA. Upon procuring exclusive license from the University of Massachussets Medical School in 2010, Ionis Pharmaceuticals (formerly ISIS Pharamaceuticals) began clinical development of Spinraza (synonyms: Nusinersen, IONIS-SMN, ISIS-SMN), an antisense drug based on ISS-N1 target. Spinraza showed very promising results at all steps of the clinical development and was approved by US Food and Drug Administration (FDA) on December 23, 2016. Spinraza is the first FDA-approved treatment for SMA and the first antisense drug to restore expression of a fully functional protein via splicing correction. The success of Spinraza underscores the potential of intronic sequences as promising therapeutic targets and sets the stage for further improvement of antisense drugs based on advanced oligonucleotide chemistries and delivery protocols.

Citing Articles

Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group.

Cavazza A, Molina-Estevez F, Plaza Reyes A, Ronco V, Naseem A, Malensek S Mol Ther Nucleic Acids. 2025; 36(1):102457.

PMID: 39991472 PMC: 11847086. DOI: 10.1016/j.omtn.2025.102457.

The evolution and application of RNA-focused small molecule libraries.

Taghavi A, Springer N, Zanon P, Li Y, Li C, Childs-Disney J RSC Chem Biol. 2025; .

PMID: 39957993 PMC: 11824871. DOI: 10.1039/d4cb00272e.

Effect of nusinersen on pulmonary function in children with spinal muscular atrophy in the plateau region: A pilot study.

Zhu J, Chen X, Sang H, Ma M, Tang C Heliyon. 2025; 11(1):e41388.

PMID: 39834441 PMC: 11743296. DOI: 10.1016/j.heliyon.2024.e41388.

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges.

Haque U, Yokota T Genes (Basel). 2024; 15(8).

PMID: 39202360 PMC: 11353366. DOI: 10.3390/genes15080999.

Rational Design Problematics of Peptide Nucleic Acids as SARS-CoV-2 Inhibitors.

Grigoreva T, Vorona S, Novikova D, Tribulovich V ACS Omega. 2024; 9(30):33000-33010.

PMID: 39100288 PMC: 11292644. DOI: 10.1021/acsomega.4c04023.

References

Kashima T, Manley J . A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet. 2003; 34(4):460-3. DOI: 10.1038/ng1207. View

Singh N, Shishimorova M, Cao L, Gangwani L, Singh R . A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol. 2009; 6(3):341-50. PMC: 2734876. DOI: 10.4161/rna.6.3.8723. View

Cartegni L, Krainer A . Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002; 30(4):377-84. DOI: 10.1038/ng854. View

Keil J, Seo J, Howell M, Hsu W, Singh R, DiDonato C . A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids. 2014; 3:e174. PMC: 4121513. DOI: 10.1038/mtna.2014.23. View

Ottesen E, Howell M, Singh N, Seo J, Whitley E, Singh R . Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy. Sci Rep. 2016; 6:20193. PMC: 4735745. DOI: 10.1038/srep20193. View

Han K, Foster D, Zhang N, Kanisha K, Dzieciatkowska M, Sclafani R . Ubiquitin-specific protease 9x deubiquitinates and stabilizes the spinal muscular atrophy protein-survival motor neuron. J Biol Chem. 2012; 287(52):43741-52. PMC: 3527959. DOI: 10.1074/jbc.M112.372318. View

Heier C, Satta R, Lutz C, DiDonato C . Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet. 2010; 19(20):3906-18. PMC: 2947406. DOI: 10.1093/hmg/ddq330. View

Hammond S, Hazell G, Shabanpoor F, Saleh A, Bowerman M, Sleigh J . Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A. 2016; 113(39):10962-7. PMC: 5047168. DOI: 10.1073/pnas.1605731113. View

Singh R, Howell M, Ottesen E, Singh N . Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech. 2017; 1860(3):299-315. PMC: 5325804. DOI: 10.1016/j.bbagrm.2016.12.008. View

10.

Williams J, Schray R, Patterson C, Ayitey S, Tallent M, Lutz G . Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci. 2009; 29(24):7633-8. PMC: 6665627. DOI: 10.1523/JNEUROSCI.0950-09.2009. View

11.

Meyer K, Marquis J, Trub J, Nlend R, Verp S, Ruepp M . Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet. 2008; 18(3):546-55. DOI: 10.1093/hmg/ddn382. View

12.

Porensky P, Mitrpant C, McGovern V, Bevan A, Foust K, Kaspar B . A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. 2011; 21(7):1625-38. PMC: 3298284. DOI: 10.1093/hmg/ddr600. View

13.

Seo J, Ottesen E, Singh R . Antisense methods to modulate pre-mRNA splicing. Methods Mol Biol. 2014; 1126:271-83. DOI: 10.1007/978-1-62703-980-2_20. View

14.

Howell M, Singh N, Singh R . Advances in therapeutic development for spinal muscular atrophy. Future Med Chem. 2014; 6(9):1081-99. PMC: 4356243. DOI: 10.4155/fmc.14.63. View

15.

Zhou H, Meng J, Marrosu E, Janghra N, Morgan J, Muntoni F . Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Hum Mol Genet. 2015; 24(22):6265-77. PMC: 4614699. DOI: 10.1093/hmg/ddv329. View

16.

Gombash S, Cowley C, Fitzgerald J, Iyer C, Fried D, McGovern V . SMN deficiency disrupts gastrointestinal and enteric nervous system function in mice. Hum Mol Genet. 2015; 24(13):3847-60. PMC: 4542833. DOI: 10.1093/hmg/ddv127. View

17.

Lunn M, Wang C . Spinal muscular atrophy. Lancet. 2008; 371(9630):2120-33. DOI: 10.1016/S0140-6736(08)60921-6. View

18.

Hsu S, Lai M, Er T, Yang S, Hung C, Tsai H . Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts. Clin Chim Acta. 2010; 411(23-24):1920-8. DOI: 10.1016/j.cca.2010.07.035. View

19.

Zhang Z, Pinto A, Wan L, Wang W, Berg M, Oliva I . Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy. Proc Natl Acad Sci U S A. 2013; 110(48):19348-53. PMC: 3845193. DOI: 10.1073/pnas.1319280110. View

20.

Mitrpant C, Porensky P, Zhou H, Price L, Muntoni F, Fletcher S . Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One. 2013; 8(4):e62114. PMC: 3632594. DOI: 10.1371/journal.pone.0062114. View